HCA HCA Healthcare, Inc. Common Stock
NYSE · Health Care · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 七月 28, 2026HCA 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
HCA 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
关于 HCA Healthcare, Inc. Common Stock 公司概况(来自维基百科)
HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
History
Early years
The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was chief executive.
The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.
Growth and merger
The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.
In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.
In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,
to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.
Columbia Hospital Corporation
In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.
In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.
Recent history
On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.
In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.
In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.
In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.
In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.
In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.
In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.
In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.
Facilities
United States
As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.
Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.
In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.
In 2019 they purchased Mission Health System which operates hospitals in North Carolina.
In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.
In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.
United Kingdom
HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:
It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.
The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.
The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.
Significant areas of operation
Medical education
In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.
Controversies
Medicare billing practices lawsuit
In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.
The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.
2005 insider trading suit
In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.
COVID-19 PPE
During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.
Mission Hospital Acquisition Complaints
On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.
On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.
来源:维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?
| 指标 | 5年趋势 | HCA | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | 14.35年均值 ≈13.8 | ≈13.8 | 16.5 | 低估 | |
| P/S (TTM) | 1.25年均值 ≈1.2 | ≈1.2 | 1.2 | 公允价值 | |
| 市净率 (MRQ) | -14.05年均值 ≈-39.2 | ≈-39.2 | · | · | |
| EV / EBITDA (企业价值 / EBITDA) | 38.75年均值 ≈37.3 | ≈37.3 | 18.9 | 估值过高 | |
| 股价/自由现金流 (TTM) | 15.55年均值 ≈14.6 | ≈14.6 | · | · | |
| 市现率 (TTM) | 8.45年均值 ≈7.9 | ≈7.9 | 9.1 | 低估 | |
| EV / Revenue (市值/营收) | 1.85年均值 ≈1.8 | ≈1.8 | · | · | |
| EV / FCF (市值/自由现金流) | 17.75年均值 ≈21.8 | ≈21.8 | · | · | |
| PEG Ratio (市盈率增长比) | ≈0.7 | · | · | · |
同行中位数按每项指标的标准化基础计算,可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率;股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | HCA | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| EBITDA Margin (息税折旧摊销前利润率) | 4.7%5年均值 ≈4.8% | ≈4.8% | 11.1% | 弱 | |
| 税前利润率 (TTM) | 12.7%5年均值 ≈13.6% | ≈13.6% | 10.3% | 顶尖 | |
| 净利润率 (TTM) | 8.8%5年均值 ≈9.3% | ≈9.3% | 7.3% | 持平 | |
| ROA (TTM) | 11.1%5年均值 ≈11.2% | ≈11.2% | 6.5% | 顶尖 | |
| ROE (TTM) | -124.0%5年均值 ≈-963.7% | ≈-963.7% | 19.1% | 弱 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | HCA | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | -6.55年均值 ≈-19.5 | ≈-19.5 | 0.1 | 低负债 | |
| 流动比率 (MRQ) | 1.05年均值 ≈1.2 | ≈1.2 | 1.2 | 低流动性 | |
| Quick Ratio (速动比率) | 0.75年均值 ≈0.9 | ≈0.9 | 0.9 | 低流动性 | |
| 长期负债/股东权益 (MRQ) | -6.55年均值 ≈-18.7 | ≈-18.7 | 0.1 | 低负债 |
成长 营收、每股收益 (EPS) 和净利润增长:同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | HCA | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 7.1%5年均值 ≈8.0% | ≈8.0% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 7.9%5年均值 ≈7.4% | ≈7.4% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 8.0% | · | · | · | |
| EPS YoY | 28.8%5年均值 ≈25.6% | ≈25.6% | · | · | |
| Net Income YoY (净利润同比增长) | 17.8%5年均值 ≈17.4% | ≈17.4% | · | · | |
| EPS CAGR 3Y (每股收益年复合增长率(3年)) | 13.9%5年均值 ≈11.8% | ≈11.8% | · | · | |
| EPS CAGR 5Y (每股收益年复合增长率(5年)) | 21.0% | · | · | · | |
| Net Income CAGR 3Y (净利润年复合增长率(3年)) | 6.3%5年均值 ≈4.0% | ≈4.0% | · | · | |
| Net Income CAGR 5Y (净利润年复合增长率(5年)) | 12.6% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | HCA | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 1.35年均值 ≈1.2 | ≈1.2 | 0.8 | 顶尖 | |
| Receivables Turnover (应收账款周转率) | 7.05年均值 ≈7.1 | ≈7.1 | 8.3 | 弱 | |
| Revenue / Employee (年营业收入 ÷ 员工人数(报告的 headcount,yfinance)。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$328.7K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
股息 收益率、派息率、股息历史、5年CAGR
| 除息日 | 金额 | 货币 | 收益率 |
|---|---|---|---|
| 九月 16, 2026 | $0.78 | USD | ≈0.71% |
| 六月 16, 2026 | $0.78 | USD | ≈0.76% |
| 三月 17, 2026 | $0.78 | USD | ≈0.58% |
| 十二月 15, 2025 | $0.72 | USD | ≈0.60% |
| 九月 16, 2025 | $0.72 | USD | ≈0.71% |
| 六月 16, 2025 | $0.72 | USD | ≈0.75% |
| 三月 17, 2025 | $0.72 | USD | ≈0.82% |
| 十二月 13, 2024 | $0.66 | USD | ≈0.84% |
| 九月 16, 2024 | $0.66 | USD | ≈0.64% |
| 六月 14, 2024 | $0.66 | USD | ≈0.75% |
| 三月 14, 2024 | $0.66 | USD | ≈0.76% |
| 十二月 13, 2023 | $0.60 | USD | ≈0.89% |
| 九月 14, 2023 | $0.60 | USD | ≈0.90% |
| 六月 15, 2023 | $0.60 | USD | ≈0.81% |
| 三月 16, 2023 | $0.60 | USD | ≈0.90% |
| 十二月 13, 2022 | $0.56 | USD | ≈0.92% |
| 九月 15, 2022 | $0.56 | USD | ≈1.0% |
| 六月 15, 2022 | $0.56 | USD | ≈1.1% |
| 三月 16, 2022 | $0.56 | USD | ≈0.75% |
| 十二月 13, 2021 | $0.48 | USD | ≈0.90% |
收益历史 每股收益实际值 vs 预估值,惊喜%,达标率,下次财报日期
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 七月 23, 2026 | $7.62 | $7.54 | 1.0% |
| 2026年3月31日 | $7.15 | $7.21 | -0.85% | |
| 2025年12月31日 | $8.14 | $7.53 | 8.0% | |
| 2025年9月30日 | $6.96 | $5.77 | 20.6% | |
| 2025年6月30日 | $6.83 | $6.31 | 8.2% | |
| 2025年3月31日 | $6.45 | $5.84 | 10.5% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| SG&A Expense | $548M | $421M | $353M | $307M | $337M | $416M | $370M | $344M | $340M | $343M | |
| Operating Expenses | $65.77B | $62.08B | $57.26B | $51.65B | $48.92B | $46.10B | $46.09B | $41.34B | $39.23B | $36.68B | |
| Interest Expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.57B | $1.58B | $1.82B | $1.75B | $1.69B | $1.71B | |
| Pretax Income | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B | $5.43B | $5.24B | $5.33B | $4.38B | $4.81B | |
| Income Tax | $2.05B | $1.87B | $1.61B | $1.75B | $2.11B | $1.04B | $1.10B | $946M | $1.64B | $1.38B | |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| EPS (Basic) | $28.70 | $22.27 | $19.25 | $19.43 | $21.52 | $11.10 | $10.27 | $10.90 | $6.12 | $7.53 | |
| EPS (Diluted) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 | |
| Shares (Basic) | 236,413,000 | 258,603,000 | 272,404,000 | 290,348,000 | 323,315,000 | 338,274,000 | 341,210,000 | 347,297,000 | 362,305,000 | 383,591,000 | |
| Shares (Diluted) | 239,495,000 | 261,806,000 | 276,412,000 | 294,666,000 | 328,752,000 | 343,605,000 | 348,226,000 | 355,303,000 | 372,221,000 | 395,851,000 | |
| EBITDA | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $1.93B | $935M | $908M | $1.45B | $1.79B | $621M | $502M | $732M | $646M | |
| Short-term Investments | · | · | · | · | · | $116M | $147M | $47M | $54M | $49M | |
| Receivables | $10.87B | $10.75B | $9.96B | $8.89B | $8.10B | $7.05B | $7.38B | $6.79B | $6.50B | $5.83B | |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B | $2.02B | $1.85B | $1.73B | $1.57B | $1.50B | |
| Other Current Assets | $2.22B | $1.99B | $2.01B | $1.78B | $2.01B | $1.46B | $1.35B | $1.19B | $1.17B | $1.11B | |
| Current Assets | $15.78B | $16.41B | $14.93B | $13.64B | $13.54B | $12.33B | $11.20B | $10.21B | $9.98B | $9.09B | |
| PP&E (Net) | $31.14B | $29.41B | $27.71B | $25.57B | $24.06B | $23.20B | $22.71B | $19.76B | $17.89B | $16.35B | |
| PP&E (Gross) | $66.28B | $62.51B | $58.55B | $54.76B | $51.35B | $49.32B | $47.23B | $42.97B | $40.08B | $37.05B | |
| Accum. Depreciation | $35.13B | $33.10B | $30.83B | $29.18B | $27.29B | $26.12B | $24.52B | $23.21B | $22.19B | $20.70B | |
| Other Non-current Assets | $255M | $230M | $184M | $298M | $598M | $546M | $480M | $690M | $710M | $1.07B | |
| Total Assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Accounts Payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B | $3.54B | $2.90B | $2.58B | $2.61B | $2.32B | |
| Current Liabilities | $16.35B | $15.18B | $12.65B | $9.90B | $9.58B | $8.70B | $7.76B | $7.57B | $6.16B | $5.83B | |
| Capital Leases | $1.85B | $1.86B | $1.90B | $1.75B | $1.75B | $1.67B | $1.50B | · | · | · | |
| Total Liabilities | · | · | · | · | · | · | $45.62B | $42.12B | $41.59B | $39.39B | |
| Long-term Debt | $44.28B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Total Debt | $41.60B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Retained Earnings | $-5.72B | $-2.12B | $-1.35B | $-2.28B | $-532M | $777M | $-2.35B | $-4.57B | $-6.53B | $-6.97B | |
| AOCI | $-305M | $-387M | $-425M | $-490M | $-404M | $-502M | $-460M | $-381M | $-278M | $-338M | |
| Stockholders' Equity | $-6.03B | $-2.50B | $-1.77B | $-2.77B | $-933M | $572M | $-2.81B | $-4.95B | $-6.81B | $-7.30B | |
| Liabilities + Equity | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Shares Outstanding | 224,605,100 | 249,981,400 | 265,537,300 | 277,378,300 | 305,476,800 | 339,425,600 | 338,445,600 | 342,895,200 | 350,091,600 | 370,535,900 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B | |
| Stock-based Comp | $401M | $360M | $262M | $341M | $440M | $362M | $347M | $268M | $270M | $251M | |
| Amort. of Intangibles | $12M | $16M | $20M | $44M | $25M | $26M | · | · | · | · | |
| Other Non-cash | $1.93B | $1.08B | $850M | $-431M | $-1.29B | $2.40B | $1.07B | $461M | $-3.53B | $-2.67B | |
| Operating Cash Flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B | |
| CapEx | $4.94B | $4.88B | $4.74B | $4.39B | $3.58B | $2.83B | $4.16B | $3.57B | $3.02B | $2.76B | |
| Investing Cash Flow | $-4.99B | $-4.93B | $-5.32B | $-3.39B | $-2.64B | $-3.39B | $-5.72B | $-3.90B | $-4.28B | $-3.24B | |
| Debt Issued | $8.47B | $7.50B | $3.22B | $6.00B | $4.34B | $2.70B | $6.45B | $2.00B | $1.50B | $5.40B | |
| Net Debt Issued | $1.08B | $5.08B | $2.31B | $3.17B | $475M | $-737M | $1.13B | $296M | $749M | $925M | |
| Stock Repurchased | $10.07B | $6.04B | $3.81B | $7.00B | $8.21B | $441M | $1.03B | $1.53B | $2.05B | $2.75B | |
| Net Stock Activity | $-10.07B | $-6.04B | $-3.81B | $-7.00B | $-8.21B | $-441M | $-1.03B | $-1.53B | $-2.05B | $-2.75B | |
| Dividends Paid | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · | |
| Financing Cash Flow | $-8.55B | $-4.58B | $-4.09B | $-5.66B | $-6.66B | $-4.68B | $-1.77B | $-3.08B | $-1.06B | $-2.51B | |
| Net Change in Cash | $-893M | $998M | $27M | $-543M | $-342M | $1.17B | $119M | $-230M | $86M | $-95M | |
| Taxes Paid | $1.74B | $1.84B | $1.39B | $1.18B | $2.18B | $1.00B | $849M | $872M | $1.21B | $1.25B | |
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B | |
| Levered FCF | $5.91B | $4.03B | $3.16B | $2.74B | $4.15B | $5.12B | $2.00B | $1.74B | $1.35B | $1.68B |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | · | · | |
| Pretax Margin | 13.0% | 12.1% | 11.9% | 14.2% | 16.7% | 10.5% | 10.2% | 11.4% | · | · | |
| EBITDA Margin | 4.7% | 4.7% | 4.7% | 4.9% | 4.9% | 5.3% | 5.1% | 4.9% | · | · | |
| ROA | 11.3% | 10.0% | 9.7% | 10.9% | 14.2% | 8.1% | 8.3% | 10.0% | 6.3% | 8.7% | |
| ROE | -159.1% | -269.6% | -230.9% | -305.0% | -3853.7% | -335.8% | -90.4% | -64.4% | -31.4% | -38.8% |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.6 | 1.6 | |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.0 | 1.2 | 1.1 | |
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 | 54.2 | -12.0 | -6.6 | -4.9 | -4.3 | |
| LT Debt / Equity | -6.9 | -15.3 | -21.0 | -13.6 | -36.8 | 53.8 | -12.0 | -6.5 | -4.8 | -4.3 |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | · | · | |
| Receivables Turnover | 7.0 | 6.8 | 6.9 | 7.1 | 7.8 | 7.1 | 7.2 | 7.0 | · | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-26.83 | $-10.00 | $-6.68 | $-9.98 | $-3.05 | $1.69 | $-8.30 | $-14.44 | $-19.44 | $-19.71 | |
| Revenue / Share | $315.66 | $269.68 | $235.04 | $204.41 | $178.71 | $149.98 | $147.42 | $131.37 | · | · | |
| Cash Flow / Share | $52.76 | $40.16 | $34.12 | $28.92 | $27.25 | $26.87 | $21.83 | $19.03 | $14.58 | $14.28 | |
| Cash / Share | $4.63 | $7.73 | $3.52 | $3.27 | $4.75 | $5.28 | $1.83 | $1.46 | $2.09 | $1.74 | |
| Dividend / Share | $2.88 | $2.64 | $2.40 | $2.24 | $1.92 | $0.43 | $1.60 | $1.40 | · | · | |
| EPS (TTM) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.1% | 8.7% | 7.9% | 2.5% | 14.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.9% | 6.3% | 8.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 28.8% | 16.0% | -0.94% | -9.5% | 93.6% | · | · | · | · | · | |
| EPS CAGR 3Y | 13.9% | 1.3% | 20.2% | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 17.8% | 9.9% | -7.1% | -18.9% | 85.3% | · | · | · | · | · | |
| Net Income CAGR 3Y | 6.3% | -6.1% | 11.8% | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 34.7% | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| Net Income TTM | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| Market Cap | $104.86B | $75.03B | $71.88B | $66.56B | $78.48B | $55.82B | $50.03B | $42.67B | $30.75B | $27.43B | |
| Enterprise Value | $145.42B | $116.13B | $110.53B | $103.74B | $111.61B | $84.92B | $82.98B | $74.95B | $63.02B | $58.11B | |
| P/E | 16.5 | 13.6 | 14.3 | 12.5 | 12.1 | 15.0 | 14.7 | 11.7 | 14.8 | 10.1 | |
| P/S | 1.4 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.0 | 0.9 | 0.7 | 0.7 | |
| P/B | -17.4 | -30.0 | -40.5 | -24.1 | -84.1 | 97.6 | -17.8 | -8.6 | -4.5 | -3.8 | |
| P / Tangible Book | · | · | · | · | · | 97.6 | · | · | · | · | |
| P / Cash Flow | 8.3 | 7.1 | 7.6 | 7.8 | 8.8 | 6.0 | 6.6 | 6.3 | 5.7 | 4.9 | |
| P / FCF | 13.6 | 13.3 | 15.3 | 16.1 | 14.6 | 8.7 | 14.5 | 13.4 | 12.8 | 9.5 | |
| EV / EBITDA | 41.3 | 35.1 | 35.9 | 34.9 | 39.1 | 31.2 | 32.0 | 32.9 | 29.6 | 29.6 | |
| EV / FCF | 18.9 | 20.6 | 23.6 | 25.1 | 20.7 | 13.3 | 24.1 | 23.5 | 26.1 | 20.1 | |
| EV / Revenue | 1.9 | 1.6 | 1.7 | 1.7 | 1.9 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | |
| Dividend Yield | 0.65% | 0.92% | 0.92% | 0.98% | 0.80% | 0.27% | 1.1% | 1.1% | 0.00% | · | |
| Earnings Yield | 6.1% | 7.3% | 7.0% | 8.0% | 8.2% | 6.7% | 6.8% | 8.6% | 6.8% | 9.9% | |
| Payout Ratio | 10.0% | 12.0% | 12.6% | 11.6% | 9.0% | 4.1% | 15.7% | 12.9% | · | · | |
| Annual Payout | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.23B | $19.11B | $19.51B | $19.16B | $18.61B | $18.32B | $18.29B | $17.49B | $17.49B | $17.34B | $17.30B | $16.21B | $15.86B | $15.59B | $15.50B | $14.97B | |
| SG&A Expense | $148M | $133M | $153M | $139M | $130M | $126M | $120M | $111M | $100M | $90M | $108M | $89M | $82M | $74M | $79M | $74M | |
| Operating Expenses | $17.74B | $16.82B | $16.84B | $16.74B | $16.19B | $15.99B | $16.15B | $15.58B | $15.26B | $15.09B | $14.96B | $14.58B | $14.05B | $13.67B | $12.20B | $13.27B | |
| Interest Expense | $599M | $584M | $572M | $561M | $568M | $547M | $528M | $515M | $506M | $512M | $491M | $483M | $485M | $479M | $453M | $446M | |
| Pretax Income | $2.49B | $2.29B | $2.67B | $2.42B | $2.42B | $2.33B | $2.13B | $1.91B | $2.24B | $2.25B | $2.35B | $1.63B | $1.81B | $1.92B | $3.30B | $1.70B | |
| Income Tax | $564M | $430M | $509M | $515M | $524M | $502M | $447M | $424M | $550M | $445M | $484M | $355M | $397M | $379M | $656M | $360M | |
| Net Income | $1.70B | $1.62B | $1.88B | $1.64B | $1.65B | $1.61B | $1.44B | $1.27B | $1.46B | $1.59B | $1.61B | $1.08B | $1.19B | $1.36B | $2.08B | $1.13B | |
| EPS (Basic) | $7.70 | $7.25 | $8.22 | $7.05 | $6.91 | $6.52 | $5.72 | $4.94 | $5.60 | $6.01 | $6.00 | $3.98 | $4.35 | $4.92 | $7.30 | $3.97 | |
| EPS (Diluted) | $7.62 | $7.15 | $8.09 | $6.96 | $6.83 | $6.45 | $5.66 | $4.88 | $5.53 | $5.93 | $5.92 | $3.91 | $4.29 | $4.85 | $7.20 | $3.91 | |
| Shares (Basic) | 220,538,000 | 223,588,000 | · | 232,891,000 | 239,173,000 | 246,936,000 | · | 256,763,000 | 261,156,000 | 264,435,000 | · | 271,173,000 | 274,494,000 | 276,910,000 | · | 285,958,000 | |
| Shares (Diluted) | 222,828,000 | 226,652,000 | · | 236,181,000 | 241,911,000 | 249,440,000 | · | 259,917,000 | 264,071,000 | 268,016,000 | · | 275,424,000 | 278,198,000 | 280,961,000 | · | 289,852,000 | |
| EBITDA | $944M | $930M | · | $889M | $863M | $860M | · | $842M | $819M | $795M | · | $769M | $763M | $756M | · | $749M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $940M | $1.04B | $997M | $939M | $1.06B | $1.93B | $2.89B | $831M | $1.28B | · | $891M | $862M | $842M | · | $999M | |
| Receivables | $12.28B | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | · | $9.18B | $8.71B | $8.66B | · | $8.55B | |
| Inventory | $1.66B | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | · | $2.03B | $2.05B | $2.08B | · | $2.01B | |
| Other Current Assets | $2.23B | $2.11B | $2.22B | $2.13B | $2.37B | $2.32B | $1.99B | $2.08B | $2.30B | $2.05B | · | $2.19B | $2.26B | $1.96B | · | $1.92B | |
| Current Assets | $17.19B | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | · | $14.29B | $13.89B | $13.54B | · | $13.48B | |
| PP&E (Net) | $31.82B | $31.47B | $31.14B | $30.57B | $30.12B | $29.74B | $29.41B | $29.05B | $28.64B | $28.10B | · | $27.12B | $26.64B | $26.05B | · | $24.98B | |
| PP&E (Gross) | $68.41B | $67.36B | $66.28B | $65.49B | $64.39B | $63.68B | $62.51B | $61.75B | $60.62B | $59.44B | · | $57.77B | $56.67B | $55.46B | · | $53.73B | |
| Accum. Depreciation | $36.59B | $35.89B | $35.13B | $34.92B | $34.27B | $33.94B | $33.10B | $32.70B | $31.99B | $31.34B | · | $30.66B | $30.02B | $29.41B | · | $28.75B | |
| Other Non-current Assets | $258M | $326M | $255M | $277M | $236M | $226M | $230M | $309M | $240M | $199M | · | $200M | $196M | $319M | · | $461M | |
| Total Assets | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B | $54.59B | $53.59B | $52.71B | $52.44B | $51.48B | |
| Accounts Payable | $4.75B | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | · | $4.14B | $3.82B | $3.77B | · | $4.16B | |
| Current Liabilities | $17.31B | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | · | $12.41B | $11.54B | $11.03B | · | $9.78B | |
| Capital Leases | $1.83B | $1.82B | $1.85B | $1.84B | $1.88B | $1.86B | $1.86B | $1.92B | $1.89B | $1.91B | · | $1.78B | $1.81B | $1.72B | · | $1.76B | |
| Long-term Debt | $45.83B | $44.37B | $44.28B | $42.60B | $42.70B | $44.58B | $43.03B | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Total Debt | $43.45B | $39.49B | · | $38.40B | $39.38B | $44.58B | · | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Retained Earnings | $-6.31B | $-5.98B | $-5.72B | $-5.02B | $-4.09B | $-3.16B | $-2.12B | $-1.81B | $-1.17B | $-1.19B | · | $-1.99B | $-1.85B | $-2.03B | · | $-2.78B | |
| AOCI | $-334M | $-327M | $-305M | $-317M | $-309M | $-357M | $-387M | $-378M | $-433M | $-433M | $-425M | $-491M | $-456M | $-470M | $-490M | $-592M | |
| Stockholders' Equity | $-6.64B | $-6.30B | $-6.03B | $-5.33B | $-4.39B | $-3.52B | $-2.50B | $-2.18B | $-1.60B | $-1.61B | · | $-2.48B | $-2.30B | $-2.50B | · | $-3.37B | |
| Liabilities + Equity | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | · | $54.59B | $53.59B | $52.71B | · | $51.48B | |
| Shares Outstanding | 217,963,300 | 222,530,900 | 224,605,100 | 229,845,100 | 236,143,900 | 242,955,400 | 249,981,400 | 254,517,700 | 259,237,600 | 263,215,800 | · | 268,967,300 | 272,931,700 | 275,939,900 | · | 283,903,500 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $944M | $930M | $911M | $889M | $863M | $860M | $856M | $842M | $819M | $795M | $789M | $769M | $763M | $756M | $750M | $749M | |
| Stock-based Comp | $85M | $86M | $100M | $104M | $99M | $98M | $85M | $76M | $112M | $87M | $57M | $72M | $56M | $77M | $83M | $87M | |
| Other Non-cash | · | $-622M | · | · | · | $-917M | · | · | · | $-4M | · | · | · | $-393M | · | · | |
| Operating Cash Flow | $2.33B | $2.01B | $2.36B | $4.42B | $4.21B | $1.65B | $2.56B | $3.52B | $1.97B | $2.47B | $2.67B | $2.48B | $2.48B | $1.80B | $2.53B | $3.02B | |
| CapEx | $1.23B | $1.12B | $1.49B | $1.29B | $1.18B | $991M | $1.28B | $1.19B | $1.28B | $1.12B | $1.16B | $1.15B | $1.24B | $1.20B | $1.32B | $1.13B | |
| Investing Cash Flow | $-1.56B | $-1.28B | $-1.32B | $-1.39B | $-1.25B | $-1.03B | $-1.35B | $-1.35B | $-1.33B | $-903M | $-1.60B | $-1.31B | $-1.26B | $-1.15B | $-793M | $-546M | |
| Debt Issued | $2.99B | $0 | $3.24B | $0 | $0 | $5.23B | $0 | $3.01B | $0 | $4.48B | $4M | $2M | $3.22B | $0 | $21M | $10M | |
| Net Debt Issued | · | $-58M | · | · | · | $1.34B | · | · | · | $2.42B | · | · | · | $-550M | · | · | |
| Stock Repurchased | $2.06B | $1.57B | $2.56B | $2.50B | $2.50B | $2.51B | $1.70B | $1.79B | $1.37B | $1.18B | $910M | $1.14B | $915M | $846M | $1.52B | $698M | |
| Net Stock Activity | · | $-1.57B | · | · | · | $-2.51B | · | · | · | $-1.18B | · | · | · | $-846M | · | · | |
| Dividends Paid | $171M | $183M | $162M | $166M | $171M | $180M | $165M | $169M | $171M | $185M | $160M | $162M | $164M | $175M | $156M | $160M | |
| Financing Cash Flow | $-704M | $-830M | $-999M | $-2.97B | $-3.09B | $-1.50B | $-2.16B | $-110M | $-1.09B | $-1.22B | $-1.04B | $-1.13B | $-1.20B | $-725M | $-1.84B | $-2.32B | |
| Net Change in Cash | $73M | $-100M | $43M | $58M | $-121M | $-873M | $-955M | $2.06B | $-453M | $349M | $44M | $29M | $20M | $-66M | $-91M | $141M | |
| Taxes Paid | $730M | $-5M | $1.51B | $81M | $136M | $10M | $358M | $487M | $998M | $1M | $316M | $297M | $766M | $7M | $244M | $322M | |
| Free Cash Flow | · | $895M | · | · | · | $660M | · | · | · | $1.35B | · | · | · | $606M | · | · | |
| Levered FCF | · | $421M | · | · | · | $231M | · | · | · | $940M | · | · | · | $221M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 8.4% | 8.5% | · | 8.6% | 8.9% | 8.8% | · | 7.3% | 8.3% | 9.2% | · | 6.7% | 7.5% | 8.7% | · | 7.6% | |
| Pretax Margin | 12.3% | 12.0% | · | 12.6% | 13.0% | 12.7% | · | 10.9% | 12.8% | 13.0% | · | 10.1% | 11.4% | 12.3% | · | 11.4% | |
| EBITDA Margin | 4.7% | 4.9% | · | 4.6% | 4.6% | 4.7% | · | 4.8% | 4.7% | 4.6% | · | 4.7% | 4.8% | 4.9% | · | 5.0% | |
| ROA | 2.8% | 2.7% | · | 2.8% | 2.8% | 2.8% | · | 2.2% | 2.6% | 2.9% | · | 2.0% | 2.3% | 2.6% | · | 2.2% | |
| ROE | -30.8% | -33.0% | · | -43.7% | -55.2% | -62.7% | · | -54.5% | -74.9% | -77.4% | · | -36.9% | -39.9% | -60.2% | · | -55.8% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.8 | · | 0.9 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | |
| Quick Ratio | 0.8 | 0.6 | · | 0.6 | 0.7 | 0.9 | · | 0.9 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -12.7 | · | -19.7 | -25.6 | -24.9 | · | -15.9 | -16.9 | -15.6 | · | -11.2 | |
| LT Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -11.7 | · | -17.5 | -22.7 | -23.0 | · | -14.9 | -15.9 | -14.6 | · | -11.1 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.8 | 1.7 | · | 1.9 | 1.8 | 1.7 | · | 1.8 | 1.8 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-30.47 | $-28.32 | · | $-23.21 | $-18.61 | $-14.48 | · | $-8.57 | $-6.17 | $-6.14 | · | $-9.21 | $-8.44 | $-9.04 | · | $-11.87 | |
| Revenue / Share | $90.79 | $84.31 | · | $81.13 | $76.91 | $73.45 | · | $67.28 | $66.24 | $64.69 | · | $58.87 | $57.01 | $55.49 | · | $51.65 | |
| Cash Flow / Share | · | $8.89 | · | · | · | $6.62 | · | · | · | $9.21 | · | · | · | $6.42 | · | · | |
| Cash / Share | $4.65 | $4.22 | · | $4.34 | $3.98 | $4.36 | · | $11.35 | $3.21 | $4.88 | · | $3.31 | $3.16 | $3.05 | · | $3.52 | |
| Dividend / Share | $0.78 | $0.78 | $0.72 | $0.72 | $0.72 | $0.72 | $0.66 | $0.66 | $0.66 | $0.66 | $0.60 | $0.60 | $0.60 | $0.60 | $0.56 | $0.56 | |
| EPS (TTM) | $29.82 | $29.03 | · | $25.90 | $23.82 | $22.52 | · | $22.26 | $21.29 | $20.05 | · | $20.25 | $20.25 | $19.86 | · | $17.61 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $78.01B | $76.39B | · | $74.37B | $72.70B | $71.58B | · | $69.62B | $68.35B | $66.72B | · | $63.16B | $61.92B | $60.88B | · | $59.80B | |
| Net Income TTM | $6.84B | $6.79B | · | $6.34B | $5.97B | $5.78B | · | $5.93B | $5.74B | $5.47B | · | $5.72B | $5.77B | $5.73B | · | $5.38B | |
| Market Cap | $84.98B | $105.31B | · | $97.96B | $90.47B | $83.95B | · | $103.44B | $83.29B | $87.79B | · | $66.16B | $82.83B | $72.76B | · | $52.18B | |
| Enterprise Value | $127.42B | $143.86B | · | $135.36B | $128.91B | $127.47B | · | $143.52B | $123.34B | $126.70B | · | $104.62B | $120.90B | $110.77B | · | $88.89B | |
| P/E | 13.1 | 16.3 | · | 16.5 | 16.1 | 15.3 | · | 18.3 | 15.1 | 16.6 | · | 12.1 | 15.0 | 13.3 | · | 10.4 | |
| P/S | 1.1 | 1.4 | · | 1.3 | 1.2 | 1.2 | · | 1.5 | 1.2 | 1.3 | · | 1.0 | 1.3 | 1.2 | · | 0.9 | |
| P/B | -12.8 | -16.7 | · | -18.4 | -20.6 | -23.9 | · | -47.4 | -52.1 | -54.4 | · | -26.7 | -36.0 | -29.2 | · | -15.5 | |
| P / Cash Flow | · | 52.3 | · | · | · | 50.8 | · | · | · | 35.6 | · | · | · | 40.4 | · | · | |
| EV / Revenue | 1.6 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.1 | 1.8 | 1.9 | · | 1.7 | 2.0 | 1.8 | · | 1.5 | |
| Dividend Yield | 0.80% | 0.65% | · | 0.70% | 0.76% | 0.82% | · | 0.66% | 0.81% | 0.76% | · | 0.99% | 0.79% | 0.89% | · | 1.2% | |
| Earnings Yield | 7.6% | 6.1% | · | 6.1% | 6.2% | 6.5% | · | 5.5% | 6.6% | 6.0% | · | 8.2% | 6.7% | 7.5% | · | 9.6% | |
| Payout Ratio | · | 11.3% | · | · | · | 11.2% | · | · | · | 11.6% | · | · | · | 12.8% | · | · | |
| Annual Payout | $682M | $682M | · | $682M | $685M | $685M | · | $685M | $678M | $671M | · | $657M | $655M | $651M | · | $645M |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度,近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| 净收入 | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| 稀释后每股收益 (EPS) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 |
| 流动比率 | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 |
| 速动比率 | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
机构持有人 (13F) 1473 家申报者 · $57.3B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 121 (-64 与上一季度对比) | 176 (+72 与上一季度对比) | 458 (-25 与上一季度对比) | 581 (+4 与上一季度对比) | -627K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6870392526 | 14716173 | 12.00% | 股份 |
| BlackRock, Inc. | $5069973824 | 13003600 | 8.85% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3954150533 | 10141708 | 6.91% | 股份 |
| Sanders Capital, LLC | $3442060818 | 8828287 | 6.01% | 股份 |
| STATE STREET CORP | $2912102056 | 7469035 | 5.09% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $1835396649 | 4707473 | 3.21% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $1423654808 | 3668008 | 2.49% | 股份 |
| First Eagle Investment Management, LLC | $1284907912 | 3295565 | 2.24% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1057704509 | 2712828 | 1.85% | 股份 |
| MORGAN STANLEY | $1008556857 | 2586771 | 1.76% | 股份 |
| GOLDMAN SACHS GROUP INC | $960811481 | 2464314 | 1.68% | 股份 |
| JPMORGAN CHASE & CO | $896800955 | 2285832 | 1.57% | 股份 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $861456107 | 2209485 | 1.50% | 股份 |
| NORGES BANK | $836457140 | 2145367 | 1.46% | 股份 |
| Capital World Investors | $770864224 | 1977121 | 1.35% | 股份 |
| Capital International Investors | $747403041 | 1916947 | 1.31% | 股份 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $709859997 | 1500000 | 1.24% | 股份 |
| NORTHERN TRUST CORP | $666150458 | 1708560 | 1.16% | 股份 |
| FMR LLC | $636503475 | 1632520 | 1.11% | 股份 |
| Invesco Ltd. | $596390232 | 1529637 | 1.04% | 股份 |
| NORDEA INVESTMENT MANAGEMENT AB | $553702529 | 1429943 | 0.97% | 股份 |
| BARCLAYS PLC | $514349127 | 1319216 | 0.90% | 股份 |
| JANUS HENDERSON GROUP PLC | $481486890 | 1017441 | 0.84% | 股份 |
| Crake Asset Management LLP | $449072183 | 1151792 | 0.78% | 股份 |
| Metropolis Capital Ltd | $430915307 | 910564 | 0.75% | 股份 |
| Darsana Capital Partners LP | $428879000 | 1100000 | 0.75% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $414565358 | 1063288 | 0.72% | 股份 |
| Legal & General Group Plc | $410992402 | 1054124 | 0.72% | 股份 |
| FRANKLIN RESOURCES INC | $399958688 | 1025824 | 0.70% | 股份 |
| Life Cycle Investment Partners Ltd | $355737196 | 912404 | 0.62% | 股份 |
| Bank of New York Mellon Corp | $350359895 | 898612 | 0.61% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $339685814 | 871235 | 0.59% | 股份 |
| ROYAL BANK OF CANADA | $320194000 | 821241 | 0.56% | 股份 |
| LYRICAL ASSET MANAGEMENT LP | $255015742 | 654071 | 0.45% | 股份 |
| BANK OF AMERICA CORP /DE/ | $238456934 | 611601 | 0.42% | 股份 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $237236367 | 608470 | 0.41% | 股份 |
| ROYAL LONDON ASSET MANAGEMENT LTD | $235649908 | 604401 | 0.41% | 股份 |
| PRINCIPAL FINANCIAL GROUP INC | $234827401 | 602290 | 0.41% | 股份 |
| UBS Group AG | $230953291 | 592355 | 0.40% | 股份 |
| National Pension Service | $230650346 | 591578 | 0.40% | 股份 |
| Russell Investments Group, Ltd. | $206832565 | 530340 | 0.36% | 股份 |
| Nuveen, LLC | $199595109 | 511927 | 0.35% | 股份 |
| Gobi Capital LLC | $195742325 | 502045 | 0.34% | 股份 |
| Cryder Capital Partners LLP | $194561738 | 499017 | 0.34% | 股份 |
| Allianz Asset Management GmbH | $181127299 | 464560 | 0.32% | 股份 |
| DEUTSCHE BANK AG\ | $175985429 | 451372 | 0.31% | 股份 |
| Swiss National Bank | $172097446 | 441400 | 0.30% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $172079393 | 441313 | 0.30% | 股份 |
| AustralianSuper Pty Ltd | $159635782 | 409438 | 0.28% | 股份 |
| HSBC HOLDINGS PLC | $158555065 | 406750 | 0.28% | 股份 |
激进投资者及 5%+ 股东 4 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan | 2026年2月10日 | 31.60% | 初始申报 | · | SEC |
| 2006年11月22日 | · | 初始申报 | · | SEC | |
| Merrill Lynch Bank USA | 2006年9月11日 | · | 初始申报 | · | SEC |
| Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC | 2006年8月4日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 92 位内幕人士 · 54 位高管 · 31 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Samuel N Hazen | CEO | 2026年2月10日 F | 64842 | 0 | 7 | $-21483290 |
| O'Boyle Michael P | President & CEO - Parallon | 2013年2月26日 A | 21429 | 0 | 0 | $0 |
| Mike A Marks | EVP and CFO | 2026年5月7日 G | 46576 | 0 | 0 | $0 |
| Bill B Rutherford | CFO and EVP | 2024年2月16日 F | 22251 | 0 | 0 | $0 |
| Russell K Harms | CFO - Central Group | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Robert Samuel Hankins JR | CFO-Outpatient Services Group | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Richard J Shallcross | CFO - Western Group | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Jeffrey T Crudele | CFO-Eastern Division | 2005年7月1日 F | 13865 | 0 | 0 | $0 |
| Erol R Akdamar | Group President | 2024年11月12日 M | 6843 | 0 | 0 | $0 |
| Timothy M Mcmanus | Group President | 2024年7月31日 M | 27008 | 0 | 0 | $0 |
| Richard A Hammett | Group President | 2024年2月16日 F | 17936 | 0 | 0 | $0 |
| Charles J Hall | Group President | 2022年11月11日 M | 202443 | 0 | 0 | $0 |
| Bruce A Moore JR | Group President - Service Line | 2022年11月11日 S | 30807 | 0 | 0 | $0 |
| Paul W Rutledge | Group President | 2012年12月31日 A | 335657 | 0 | 0 | $0 |
| Beverly B Wallace | President - Parallon | 2011年11月2日 M | 144714 | 0 | 0 | $0 |
| Charles Robert Evans | President - Eastern Group | 2006年7月26日 A | 62173 | 0 | 0 | $0 |
| Marilyn B Tavenner | President-Outpatient Svcs Grp | 2005年10月27日 A | 26154 | 0 | 0 | $0 |
| Greg Roth | President-Ambulatory Surgery | 2004年10月31日 D | 9029 | 0 | 0 | $0 |
| Jay Grinney | President-Eastern Group | 2004年5月7日 D | 24177 | 0 | 0 | $0 |
| Jon M Foster | EVP and COO | 2026年2月10日 F | 23062 | 0 | 0 | $0 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 2026年8月26日 J | 0 | 0 | 2 | $-2747520 |
| Jennifer Berres | SVP & Chief Human Res. Officer | 2026年2月11日 S | 11993 | 0 | 2 | $-4126932 |
| Christopher F. Wyatt | SVP & Controller | 2026年2月11日 S | 44379 | 0 | 1 | $-2020000 |
| Erica Rossitto | SVP & Chief Nurse Executive | 2026年2月10日 F | 10407 | 0 | 0 | $0 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 2026年2月10日 F | 32080 | 0 | 1 | $-747135 |
| Sammie S Mosier | SVP & Chief Nurse Executive | 2025年2月13日 F | 11113 | 0 | 0 | $0 |
| Kathleen M Whalen | SVP & Chief Ethics Officer | 2024年11月14日 S | 9454 | 0 | 0 | $0 |
| Phillip G Billington | SVP-Internal Audit Services | 2024年11月12日 M | 52702 | 0 | 0 | $0 |
| Joseph A Sowell III | SVP; Chief Development Officer | 2024年8月5日 G | 18526 | 0 | 0 | $0 |
| Deborah M Reiner | SVP - Mktg. & Communications | 2024年7月29日 S | 3510 | 0 | 0 | $0 |
| Kathryn A. Torres | SVP-Payer Contracting & Align. | 2024年7月25日 S | 17755 | 0 | 0 | $0 |
| Jeffrey E. Cohen | SVP-Government Relations | 2024年5月9日 S | 5185 | 0 | 0 | $0 |
| Chad J Wasserman | SVP and CIO | 2024年3月18日 M | 1576 | 0 | 0 | $0 |
| Martin P. Paslick | SVP and CIO | 2023年4月12日 M | 24643 | 0 | 0 | $0 |
| Jane D. Englebright | SVP and Chief Nursing Officer | 2021年11月9日 S | 0 | 0 | 0 | $0 |
| Robert A Waterman | SVP & General Counsel | 2021年5月5日 S | 50062 | 0 | 0 | $0 |
| William J Morrow | SVP - Finance and Treasurer | 2021年2月18日 F | 5578 | 0 | 0 | $0 |
| Sandra L. Morgan | SVP-Provider Relations | 2021年2月18日 F | 10122 | 0 | 0 | $0 |
| Victor L Campbell | SVP-Government Affairs | 2019年5月1日 A | 194145 | 0 | 0 | $0 |
| John M Steele | SVP & Chief Human Res. Officer | 2019年2月25日 M | 84157 | 0 | 0 | $0 |
| Milton R Johnson | Chairman | 2019年2月25日 M | 881823 | 0 | 0 | $0 |
| Ravi S. Chari | SVP-Clinical Excellence | 2018年2月25日 M | 7003 | 0 | 0 | $0 |
| Alan R Yuspeh | SVP & Chief Ethics Officer | 2018年2月25日 M | 35546 | 0 | 0 | $0 |
| Joseph N Steakley | SVP-Internal Audit Services | 2018年2月25日 M | 65199 | 0 | 0 | $0 |
| Jana Joustra Davis | SVP - Mktg. & Corp. Affairs | 2017年5月23日 M | 26378 | 0 | 0 | $0 |
| David Gwin Anderson | SVP - Finance | 2016年11月7日 M | 110167 | 0 | 0 | $0 |
| Donald W Stinnett | SVP & Controller | 2016年2月25日 A | 51965 | 0 | 0 | $0 |
| Noel B Williams | SVP and CIO | 2012年5月16日 M | 299030 | 0 | 0 | $0 |
| Jack O Bovender JR | Chairman | 2009年10月6日 A | 188340 | 0 | 0 | $0 |
| Carl V George | SVP - Development | 2009年2月27日 M | 13092 | 0 | 0 | $0 |
| Patricia T Lindler | SVP - Government Programs | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Rosalyn S Elton | SVP-Operations Finance | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Frank M Houser MD | SVP-Quality & Medical Director | 2006年7月26日 A | 46145 | 0 | 0 | $0 |
| James A Fitzgerald JR | SVP-Supply Chain Operations | 2006年1月29日 F | 20674 | 0 | 0 | $0 |
| Andrea B Smith | 董事 | 2026年4月28日 A | 4666 | 0 | 0 | $0 |
| William R Frist | 董事 | 2026年4月28日 A | 13740 | 0 | 0 | $0 |
| Wayne Joseph Riley | 董事 | 2026年4月28日 A | 15029 | 0 | 0 | $0 |
| Hugh F Johnston | 董事 | 2026年4月28日 A | 4475 | 0 | 0 | $0 |
| Thomas F Frist III | 董事 | 2026年4月28日 A | 15858 | 0 | 0 | $0 |
| Michael W Michelson | 董事 | 2026年4月28日 A | 12576 | 0 | 0 | $0 |
| Nancy Ann Deparle | 董事 | 2026年4月28日 A | 21910 | 0 | 0 | $0 |
| John Chidsey | 董事 | 2026年4月28日 A | 1305 | 0 | 0 | $0 |
| Robert J Dennis | 董事 | 2025年4月29日 A | 26601 | 0 | 0 | $0 |
| Meg Crofton | 董事 | 2024年4月29日 A | 6331 | 0 | 0 | $0 |
| Charles O Holliday JR | 董事 | 2022年4月25日 A | 18955 | 0 | 0 | $0 |
| Geoffrey G Meyers | 董事 | 2019年5月1日 A | 39153 | 0 | 0 | $0 |
| John W Rowe | 董事 | 2019年5月1日 A | 30388 | 0 | 0 | $0 |
| Ann H Lamont | 董事 | 2018年5月2日 A | 17661 | 0 | 0 | $0 |
| Jay O Light | 董事 | 2017年5月3日 A | 30953 | 0 | 0 | $0 |
| Stephen G Pagliuca | 董事 | 2014年12月5日 D | 7612921 | 0 | 0 | $0 |
| Christopher R Gordon | 董事 | 2013年11月1日 D | 30003156 | 0 | 0 | $0 |
| John Connaughton | 董事 | 2013年11月1日 D | 30003156 | 0 | 0 | $0 |
| John H Mcarthur | 董事 | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Kent C Nelson | 董事 | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Magdalena Averhoff MD | 董事 | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Glenda A Hatchett | 董事 | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Frederick W Gluck | 董事 | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Harold T Shapiro | 董事 | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Michael C Armstrong | 董事 | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Martin Feldstein | 董事 | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Michael T Long | 董事 | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| ROYAL FRANK S | 董事 | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Patricia F Elcan | 10% 所有者 | 2026年2月6日 J | 36557141 | 0 | 0 | $0 |
| Frisco Holding II | 10% 所有者 | 2026年2月6日 J | 36557141 | 0 | 0 | $0 |
| HERCULES HOLDING II, LLC | 10% 所有者 | 2026年2月6日 J | 32282889 | 0 | 0 | $0 |
| Thomas F Frist JR | 10% 所有者 | 2026年2月6日 J | 36557141 | 0 | 0 | $0 |
| Patricia C Frist | 10% 所有者 | 2018年2月20日 G | 0 | 0 | 0 | $0 |
| KKR PEI GP LTD | 10% 所有者 | 2014年4月1日 J | 0 | 0 | 0 | $0 |
| Jonathan B Perlin | · | 2021年8月2日 S | 44348 | 0 | 0 | $0 |
| Juan Vallarino | · | 2016年5月9日 M | 61036 | 0 | 0 | $0 |
| Richard M Bracken | · | 2014年12月31日 F | 82499 | 0 | 0 | $0 |
| BANK OF AMERICA CORP /DE/ | · | 2012年11月6日 S | 2652364 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士;净额=仅公开市场买卖
ETF持仓 由 141 只交易所交易基金持有
权重仅反映直接股权持仓(N-PORT);杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| BUL · Pacer Funds Trust | 5.07% | 16545 NS | 2026年7月31日 | N-PORT |
| IHF · iShares Trust | 4.75% | 147977 SH | 2026年9月11日 | 每日 |
| STNC · Hennessy Funds Trust | 3.17% | 7315 NS | 2026年7月31日 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 2.45% | 97235 SH | 2026年10月2日 | 每日 |
| COWZ · Pacer Funds Trust | 2.07% | 960711 NS | 2026年7月31日 | N-PORT |
| WLTG · ETF Opportunities Trust | 2.06% | 3942 NS | 2026年7月31日 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.66% | 34083 SH | 2026年10月2日 | 每日 |
| RPG · Invesco Exchange-Traded Fund Trust | 1.27% | 58580 SH | 2026年10月2日 | 每日 |
| FLAG · Global X Funds | 1.14% | 48 NS | 2026年7月31日 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1.03% | 6909 NS | 2026年7月31日 | N-PORT |
| IYH · iShares Trust | 1.01% | 87417 SH | 2026年9月11日 | 每日 |
| SRHQ · Elevation Series Trust | 0.94% | 4938 NS | 2026年7月31日 | N-PORT |
| NEAR · iShares U.S. ETF Trust | 0.92% | 48109000 SH | 2026年9月11日 | 每日 |
| FHLC · FIDELITY COVINGTON TRUST | 0.91% | 74445 NS | 2026年7月31日 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.90% | 470451 SH | 2026年8月19日 | 每日 |
| FXH · First Trust Exchange-Traded Alpha... | 0.87% | 22725 NS | 2026年7月31日 | N-PORT |
| DIVB · iShares Trust | 0.87% | 42100 SH | 2026年9月11日 | 每日 |
| NFRA · FlexShares Trust | 0.84% | 62628 NS | 2026年7月31日 | N-PORT |
| IXJ · iShares Trust | 0.83% | 81708 SH | 2026年9月11日 | 每日 |
| SPVM · Invesco Exchange-Traded Fund Trust | 0.80% | 2483 SH | 2026年10月2日 | 每日 |
| QUVU · Hartford Funds Exchange-Traded Trust | 0.79% | 3522 NS | 2026年7月31日 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Inde... | 0.78% | 23458000 | 2026年10月2日 | 每日 |
| BSCS · Invesco Exchange-Traded Self-Inde... | 0.74% | 25897000 | 2026年10月1日 | 每日 |
| CURE · Direxion Shares ETF Trust | 0.72% | 3056 NS | 2026年7月31日 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.67% | 12075 SH | 2026年8月19日 | 每日 |
| LGDX · Tidal Trust III | 0.66% | 2345 NS | 2026年7月31日 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.55% | 11876 SH | 2026年8月19日 | 每日 |
| BSCR · Invesco Exchange-Traded Self-Inde... | 0.50% | 23126000 | 2026年10月2日 | 每日 |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0.46% | 7404 NS | 2026年7月31日 | N-PORT |
| WLDR · Two Roads Shared Trust | 0.43% | 964 NS | 2026年7月31日 | N-PORT |
| ROUS · Lattice Strategies Trust | 0.42% | 7289 NS | 2026年7月31日 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trus... | 0.40% | 92161 SH | 2026年10月2日 | 每日 |
| QLC · FlexShares Trust | 0.39% | 9856 NS | 2026年7月31日 | N-PORT |
| XOEF · iShares Trust | 0.37% | 194 SH | 2026年9月11日 | 每日 |
| GSY · Invesco Actively Managed Exchange... | 0.36% | 14000000 | 2026年10月2日 | 每日 |
| UPSD · ETF Series Solutions | 0.33% | 972 NS | 2026年7月31日 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Inde... | 0.33% | 9324000 | 2026年10月2日 | 每日 |
| MGV · VANGUARD WORLD FUND | 0.29% | 97604 SH | 2026年8月19日 | 每日 |
| PFIG · Invesco Exchange-Traded Fund Trus... | 0.28% | 390000 | 2026年10月2日 | 每日 |
| JPUS · J.P. Morgan Exchange-Traded Fund ... | 0.28% | 3186 NS | 2026年7月31日 | N-PORT |
| USXF · iShares Trust | 0.26% | 9226 SH | 2026年9月11日 | 每日 |
| IUS · Invesco Exchange-Traded Self-Inde... | 0.26% | 5813 SH | 2026年10月2日 | 每日 |
| IWX · iShares Trust | 0.23% | 21535 SH | 2026年9月11日 | 每日 |
| VTV · VANGUARD INDEX FUNDS | 0.23% | 1475731 SH | 2026年8月19日 | 每日 |
| JMOM · J.P. Morgan Exchange-Traded Fund ... | 0.23% | 14235 NS | 2026年7月31日 | N-PORT |
| MPLY · Strategy Shares | 0.22% | 87 NS | 2026年7月31日 | N-PORT |
| EUSA · iShares, Inc. | 0.21% | 9589 SH | 2026年9月11日 | 每日 |
| RSP · Invesco Exchange-Traded Fund Trust | 0.21% | 462724 SH | 2026年10月2日 | 每日 |
| FTC · First Trust Exchange-Traded Alpha... | 0.20% | 6420 NS | 2026年7月31日 | N-PORT |
| SIZE · iShares Trust | 0.19% | 1920 SH | 2026年9月11日 | 每日 |
| DYNF · BlackRock ETF Trust | 0.19% | 183934 SH | 2026年9月11日 | 每日 |
| VMAX · Lattice Strategies Trust | 0.19% | 228 NS | 2026年7月31日 | N-PORT |
| DSI · iShares Trust | 0.19% | 23734 SH | 2026年9月11日 | 每日 |
| ILCV · iShares Trust | 0.18% | 5870 SH | 2026年9月10日 | 每日 |
| IVW · iShares Trust | 0.18% | 331185 SH | 2026年9月11日 | 每日 |
| IUSG · iShares Trust | 0.17% | 136713 SH | 2026年9月11日 | 每日 |
| VOOG · VANGUARD ADMIRAL FUNDS | 0.17% | 115334 SH | 2026年8月19日 | 每日 |
| IWD · iShares Trust | 0.17% | 332035 SH | 2026年9月11日 | 每日 |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.16% | 90157 SH | 2026年8月19日 | 每日 |
| OMFL · Invesco Exchange-Traded Self-Inde... | 0.16% | 17773 SH | 2026年10月2日 | 每日 |
| USMV · iShares Trust | 0.16% | 89855 SH | 2026年9月11日 | 每日 |
| ACWV · iShares, Inc. | 0.15% | 11903 SH | 2026年9月11日 | 每日 |
| EGLE · Global X Funds | 0.15% | 8 NS | 2026年7月31日 | N-PORT |
| GLBL · Pacer Funds Trust | 0.15% | 4 NS | 2026年7月31日 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.14% | 33327 SH | 2026年10月2日 | 每日 |
| VOXP · Advisors Series Trust | 0.13% | 18 NS | 2026年7月31日 | N-PORT |
| VRIG · Invesco Actively Managed Exchange... | 0.12% | 2250000 | 2026年10月1日 | 每日 |
| TOPC · iShares Trust | 0.12% | 95 SH | 2026年9月11日 | 每日 |
| DGRO · iShares Trust | 0.12% | 120741 SH | 2026年9月11日 | 每日 |
| XVV · iShares Trust | 0.11% | 1790 SH | 2026年9月11日 | 每日 |
| QVML · Invesco Exchange-Traded Fund Trus... | 0.11% | 4410 SH | 2026年10月2日 | 每日 |
| IWL · iShares Trust | 0.11% | 5786 SH | 2026年9月11日 | 每日 |
| MGC · VANGUARD WORLD FUND | 0.11% | 31176 SH | 2026年8月19日 | 每日 |
| ACIO · ETF Series Solutions | 0.11% | 6205 NS | 2026年7月31日 | N-PORT |
| EVUS · iShares Trust | 0.10% | 934 SH | 2026年9月11日 | 每日 |
| ADME · ETF Series Solutions | 0.10% | 751 NS | 2026年7月31日 | N-PORT |
| XRMI · Global X Funds | 0.10% | 126 NS | 2026年7月31日 | N-PORT |
| XCLR · Global X Funds | 0.10% | 9 NS | 2026年7月31日 | N-PORT |
| XYLD · Global X Funds | 0.10% | 8148 NS | 2026年7月31日 | N-PORT |
| XTR · Global X Funds | 0.10% | 12 NS | 2026年7月31日 | N-PORT |
| BKLC · BNY Mellon ETF Trust | 0.10% | 13621 NS | 2026年7月31日 | N-PORT |
| VV · VANGUARD INDEX FUNDS | 0.10% | 181364 SH | 2026年8月19日 | 每日 |
| ESGV · VANGUARD WORLD FUND | 0.10% | 33758 SH | 2026年8月19日 | 每日 |
| IVV · iShares Trust | 0.10% | 1957485 SH | 2026年9月11日 | 每日 |
| PBUS · Invesco Exchange-Traded Fund Trus... | 0.10% | 26839 SH | 2026年10月2日 | 每日 |
| PTLC · Pacer Funds Trust | 0.10% | 7919 NS | 2026年7月31日 | N-PORT |
| FAD · First Trust Exchange-Traded Alpha... | 0.10% | 1395 NS | 2026年7月31日 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0.10% | 877 SH | 2026年10月2日 | 每日 |
| ILCB · iShares Trust | 0.10% | 2915 SH | 2026年9月11日 | 每日 |
| EQAL · Invesco Exchange-Traded Fund Trus... | 0.10% | 1794 SH | 2026年10月2日 | 每日 |
| BBUS · J.P. Morgan Exchange-Traded Fund ... | 0.09% | 20766 NS | 2026年7月31日 | N-PORT |
| IYY · iShares Trust | 0.09% | 6693 SH | 2026年9月11日 | 每日 |
| VOTE · TCW ETF Trust | 0.09% | 2545 NS | 2026年7月31日 | N-PORT |
| FEX · First Trust Exchange-Traded Alpha... | 0.09% | 3614 NS | 2026年7月31日 | N-PORT |
| XYLG · Global X Funds | 0.09% | 147 NS | 2026年7月31日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.09% | 46791 NS | 2026年7月31日 | N-PORT |
| IWB · iShares Trust | 0.09% | 103721 SH | 2026年9月11日 | 每日 |
| VOO · VANGUARD INDEX FUNDS | 0.09% | 4034357 SH | 2026年8月19日 | 每日 |
| TOV · EA Series Trust | 0.09% | 607 NS | 2026年7月31日 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.09% | 586 NS | 2026年7月31日 | N-PORT |
| ITOT · iShares Trust | 0.09% | 202387 SH | 2026年9月11日 | 每日 |
| ACVF · ETF Opportunities Trust | 0.09% | 337 NS | 2026年7月31日 | N-PORT |
| GTOS · Invesco Actively Managed Exchange... | 0.09% | 104000 | 2026年10月2日 | 每日 |
| QDPL · Pacer Funds Trust | 0.09% | 3708 NS | 2026年7月31日 | N-PORT |
| IWV · iShares Trust | 0.09% | 41034 SH | 2026年9月11日 | 每日 |
| DFAU · Dimensional ETF Trust | 0.08% | 25516 NS | 2026年7月31日 | N-PORT |
| CRBN · iShares Trust | 0.08% | 2269 SH | 2026年9月11日 | 每日 |
| TOK · iShares Trust | 0.08% | 451 SH | 2026年9月11日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.08% | 4930930 SH | 2026年8月19日 | 每日 |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.08% | 24633 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.08% | 12577 SH | 2026年8月19日 | 每日 |
| PHDG · Invesco Actively Managed Exchange... | 0.08% | 116 SH | 2026年10月2日 | 每日 |
| HCMT · Direxion Shares ETF Trust | 0.08% | 1081 NS | 2026年7月31日 | N-PORT |
| TILT · FlexShares Trust | 0.08% | 4108 NS | 2026年7月31日 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0.07% | 12141 NS | 2026年7月31日 | N-PORT |
| URTH · iShares, Inc. | 0.07% | 14079 SH | 2026年9月11日 | 每日 |
| ACWI · iShares Trust | 0.06% | 50294 SH | 2026年9月11日 | 每日 |
| HDUS · Lattice Strategies Trust | 0.05% | 275 NS | 2026年7月31日 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY IND... | 0.05% | 125729 SH | 2026年8月19日 | 每日 |
| DCOR · Dimensional ETF Trust | 0.05% | 3816 NS | 2026年7月31日 | N-PORT |
| GLOF · iShares Trust | 0.04% | 202 SH | 2026年9月11日 | 每日 |
| DUHP · Dimensional ETF Trust | 0.04% | 10761 NS | 2026年7月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.02% | 28662 NS | 2026年7月31日 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.02% | 1127 NS | 2026年7月31日 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.01% | 99 NS | 2026年7月31日 | N-PORT |
| GTO · Invesco Actively Managed Exchange... | 0.00% | 42000 | 2026年9月30日 | 每日 |
| CBLS · Elevation Series Trust | -1.12% | -1546 NS | 2026年7月31日 | N-PORT |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 每日 |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 每日 |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 每日 |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 每日 |
| VUSB · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 每日 |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 2026年7月15日 | 每日 |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 2026年7月15日 | 每日 |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 2026年7月15日 | 每日 |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月15日 | 每日 |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月15日 | 每日 |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月15日 | 每日 |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月30日 | 每日 |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月30日 | 每日 |
| VCEB · VANGUARD WORLD FUND | · | · | 2026年7月30日 | 每日 |
HCA 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
12个月价格目标
22 位分析师 · 2026-09-28平均目标 $454.23 +6.5%
同行比较(GICS 子行业) 关键指标与行业同行对比
财年依据,价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | · |
| THC | $17.28B | 12.8 | 3.1% | 11.1% | 56.4% | · |
| EHC | $10.61B | 19.2 | 10.5% | 9.5% | 25.1% | · |
| UHS | · | 9.4 | 9.7% | 8.6% | 21.4% | · |
| ENSG | $10.12B | 29.8 | 18.7% | 6.8% | 16.9% | · |
| PACS | $6.01B | 31.5 | 29.3% | 3.6% | 23.1% | · |
| CON | $2.53B | 15.1 | 13.9% | 7.7% | 49.8% | · |
| BKD | $2.57B | -9.6 | 2.2% | -8.2% | -313.2% | 26.2% |
| ACHC | $1.28B | -1.2 | 5.0% | -33.3% | -43.9% | · |
| SNDA | $612M | -7.7 | 25.2% | -18.6% | -197.2% | · |
最新新闻 提及该公司的近期头条新闻
交易信号 近期买入/卖出信号,包含入场价和风险/回报比
目前没有公开信号 — 没有卡片被填写,这是诚实的。
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存,并会跟随您浏览所有股票。